Physical and chemical properties of radionuclide therapy

Barry W. Wessels, Claude F. Meares

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

As more radionuclide therapies move from laboratory feasibility studies into clinical reality, it becomes increasingly important for the labeling chemistry to produce consistently a stable radiopharmaceutical that remains intact under the challenge of human catabolism. Similarly, once proof of principle is established to bring a radionuclide conjugate into clinical therapy trials, dosimetric estimates should be made to select the appropriate radionuclide properties, which are based on animal-specific or patient- specific pharmacokinetics and match a set of specific clinical endpoints. These properties may include the radionuclide physical half-life, radiolabeled conjugate biological uptake and clearance, product-specific activity, range and type of emissions, and resultant effects on tumor and normal tissue cellular survival. The immunologist and labeling chemist have now produced a variety of strategies that have potential to increase the therapeutic ratio (tumor-to-normal tissue dose ratio). The advent of normal tissue clearing agents, fragmented or chimerized carriers to improve targeting, and the method of bispecific or two-step and three-step targeting agents has increased the need for realistic modeling of the carrier in vivo to guide prospectively the competitive development of these radiopharmaceuticals. In this article, examples have been taken from the literature to elucidate the benchmark of success that careful experimental design has fostered to bring these agents into clinical practice by creative and logical methodologies. Copyright (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalSeminars in Radiation Oncology
Volume10
Issue number2
StatePublished - 2000

Fingerprint

Radioisotopes
chemical properties
radioactive isotopes
therapy
physical properties
Radiopharmaceuticals
marking
catabolism
tumors
Benchmarking
Tissue Survival
clearing
clearances
Feasibility Studies
Therapeutics
half life
Half-Life
animals
Neoplasms
Research Design

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Wessels, B. W., & Meares, C. F. (2000). Physical and chemical properties of radionuclide therapy. Seminars in Radiation Oncology, 10(2), 115-122.

Physical and chemical properties of radionuclide therapy. / Wessels, Barry W.; Meares, Claude F.

In: Seminars in Radiation Oncology, Vol. 10, No. 2, 2000, p. 115-122.

Research output: Contribution to journalArticle

Wessels, BW & Meares, CF 2000, 'Physical and chemical properties of radionuclide therapy', Seminars in Radiation Oncology, vol. 10, no. 2, pp. 115-122.
Wessels, Barry W. ; Meares, Claude F. / Physical and chemical properties of radionuclide therapy. In: Seminars in Radiation Oncology. 2000 ; Vol. 10, No. 2. pp. 115-122.
@article{97ab642059604ff0b14256fe015853f3,
title = "Physical and chemical properties of radionuclide therapy",
abstract = "As more radionuclide therapies move from laboratory feasibility studies into clinical reality, it becomes increasingly important for the labeling chemistry to produce consistently a stable radiopharmaceutical that remains intact under the challenge of human catabolism. Similarly, once proof of principle is established to bring a radionuclide conjugate into clinical therapy trials, dosimetric estimates should be made to select the appropriate radionuclide properties, which are based on animal-specific or patient- specific pharmacokinetics and match a set of specific clinical endpoints. These properties may include the radionuclide physical half-life, radiolabeled conjugate biological uptake and clearance, product-specific activity, range and type of emissions, and resultant effects on tumor and normal tissue cellular survival. The immunologist and labeling chemist have now produced a variety of strategies that have potential to increase the therapeutic ratio (tumor-to-normal tissue dose ratio). The advent of normal tissue clearing agents, fragmented or chimerized carriers to improve targeting, and the method of bispecific or two-step and three-step targeting agents has increased the need for realistic modeling of the carrier in vivo to guide prospectively the competitive development of these radiopharmaceuticals. In this article, examples have been taken from the literature to elucidate the benchmark of success that careful experimental design has fostered to bring these agents into clinical practice by creative and logical methodologies. Copyright (C) 2000 by W.B. Saunders Company.",
author = "Wessels, {Barry W.} and Meares, {Claude F.}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "115--122",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Physical and chemical properties of radionuclide therapy

AU - Wessels, Barry W.

AU - Meares, Claude F.

PY - 2000

Y1 - 2000

N2 - As more radionuclide therapies move from laboratory feasibility studies into clinical reality, it becomes increasingly important for the labeling chemistry to produce consistently a stable radiopharmaceutical that remains intact under the challenge of human catabolism. Similarly, once proof of principle is established to bring a radionuclide conjugate into clinical therapy trials, dosimetric estimates should be made to select the appropriate radionuclide properties, which are based on animal-specific or patient- specific pharmacokinetics and match a set of specific clinical endpoints. These properties may include the radionuclide physical half-life, radiolabeled conjugate biological uptake and clearance, product-specific activity, range and type of emissions, and resultant effects on tumor and normal tissue cellular survival. The immunologist and labeling chemist have now produced a variety of strategies that have potential to increase the therapeutic ratio (tumor-to-normal tissue dose ratio). The advent of normal tissue clearing agents, fragmented or chimerized carriers to improve targeting, and the method of bispecific or two-step and three-step targeting agents has increased the need for realistic modeling of the carrier in vivo to guide prospectively the competitive development of these radiopharmaceuticals. In this article, examples have been taken from the literature to elucidate the benchmark of success that careful experimental design has fostered to bring these agents into clinical practice by creative and logical methodologies. Copyright (C) 2000 by W.B. Saunders Company.

AB - As more radionuclide therapies move from laboratory feasibility studies into clinical reality, it becomes increasingly important for the labeling chemistry to produce consistently a stable radiopharmaceutical that remains intact under the challenge of human catabolism. Similarly, once proof of principle is established to bring a radionuclide conjugate into clinical therapy trials, dosimetric estimates should be made to select the appropriate radionuclide properties, which are based on animal-specific or patient- specific pharmacokinetics and match a set of specific clinical endpoints. These properties may include the radionuclide physical half-life, radiolabeled conjugate biological uptake and clearance, product-specific activity, range and type of emissions, and resultant effects on tumor and normal tissue cellular survival. The immunologist and labeling chemist have now produced a variety of strategies that have potential to increase the therapeutic ratio (tumor-to-normal tissue dose ratio). The advent of normal tissue clearing agents, fragmented or chimerized carriers to improve targeting, and the method of bispecific or two-step and three-step targeting agents has increased the need for realistic modeling of the carrier in vivo to guide prospectively the competitive development of these radiopharmaceuticals. In this article, examples have been taken from the literature to elucidate the benchmark of success that careful experimental design has fostered to bring these agents into clinical practice by creative and logical methodologies. Copyright (C) 2000 by W.B. Saunders Company.

UR - http://www.scopus.com/inward/record.url?scp=0034086254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034086254&partnerID=8YFLogxK

M3 - Article

C2 - 10727600

AN - SCOPUS:0034086254

VL - 10

SP - 115

EP - 122

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2

ER -